This handout is for hypertensive emergency in kidney transplant recipient (cni / rejection / tras / native disease recurrence). Your care team identified this based on: kidney transplant recipient + new sbp ≥180 or dbp ≥120 (or ≥30 mmhg above baseline) — multifactorial etiology screen (kdigo 2020 bp transplant).
Other reasons your team may use this plan: transplant + acute cr rise (≥25% from baseline) + new severe htn → suspect acute rejection / tras / cni toxicity; transplant + recent cni dose change / new cyp3a4 interaction (azole, macrolide, diltiazem) → drug-interaction-driven htn; transplant + graft tenderness (rejection) or new bruit over graft (tras) + severe htn.
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| nicardipine | 5 mg/h IV, titrate by 2.5 mg/h q5-15 min, max 15 mg/h | IV | continuous | KDIGO 2020 BP transplant first-line — renal-friendly DHP-CCB; minimal CYP3A4 effect on tacrolimus (unlike diltiazem/verapamil); predictable titration; preserves graft perfusion |
| labetalol | 20 mg IV q10 min (max 300 mg cumulative) OR 0.5-2 mg/min infusion | IV | bolus or infusion | KDIGO 2020 second-line — mixed α/β; useful when sympathetic drive high; minimal CNI interaction |
| amlodipine | 5-10 mg PO daily | PO | daily | KDIGO 2020 long-term first-line — DHP-CCB; minimal CYP3A4 interaction; does NOT increase rejection (legacy concern disproven); proven safe in transplant cohorts |
| lisinopril | 5 mg PO daily, titrate to 10-40 mg | PO | daily | KDIGO 2020 — add ACEi/ARB AFTER acute phase resolves + Cr stable × 7 d; reno-protective in proteinuric nephropathy; HOLD acutely if rising Cr |
| empagliflozin | 10 mg PO daily | PO | daily | EMPA-KIDNEY 2023 — reno-protective in CKD; emerging evidence in transplant (DAPA-CKD post-hoc subgroup); avoid if active UTI or recent transplant <3 mo (caution) |
| AVOID nitroprusside if eGFR <30 | AVOID | N/A | N/A | Cyanide / thiocyanate accumulation in renal impairment; ACC/AHA 2025 AVOID in eGFR <30; common pitfall in transplant cohort given graft dysfunction |
| AVOID ACEi/ARB acutely if rising Cr | HOLD ACUTELY | N/A | N/A | Efferent arteriolar vasodilation worsens AKI in volume-depleted or rejecting graft; KDIGO 2020 — restart only after Cr stable × 7 d with q3-7d monitoring |
| AVOID diltiazem/verapamil long-term as monotherapy | AVOID OR INTENTIONAL DOSE-SPARING | N/A | N/A | CYP3A4 inhibition increases tacrolimus 30-50% — sometimes used INTENTIONALLY to reduce CNI dose (cost / nephrotoxicity reduction); requires close trough monitoring; not for de novo HTN management |
Plan: HTN emergency in kidney transplant — etiology-specific (CNI toxicity / rejection / TRAS / volume / native disease) + drug-interaction-aware
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
Transition to oral 4-tier ladder once stable × 12-24 h (amlodipine + thiazide-like + ACEi/ARB once Cr stable + BB if cardiac indication); long-term BP target <130/80 per KDIGO 2020; lifelong CNI level monitoring (q1-3 mo); annual cardiac surveillance (CV is leading cause of death in transplant); CMV/BK PCR per local protocol; DSA monitoring annually; vaccination updates (avoid live); cancer surveillance (skin, PTLD)
Guideline: KDIGO 2020 BP Management in Kidney Transplant Recipients + KDIGO 2009 Transplant Recipient Care (Kasiske AJT 2010 PMID 19845597) + 2025 ACC/AHA HTN Guideline (Whelton) + ESC/ESH 2024 HTN (Mancia PMID 38613493)